<DOC>
	<DOCNO>NCT02093351</DOCNO>
	<brief_summary>This open-label 2-part Phase I study patient advance solid tumour . Part A study ( mandatory ) ass effect olaparib pharmacokinetics ( PK ) anastrozole , letrozole tamoxifen vice versa ; Part B allow patient ( eligible ) continue access olaparib PK phase provide additional safety data .</brief_summary>
	<brief_title>To Assess Safety Effect Olaparib Pharmacokinetics Anastrozole , Letrozole &amp; Tamoxifen , Their Effect Olaparib , Patients With Advanced Solid Cancer</brief_title>
	<detailed_description />
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>1 . Provision write informed consent prior study specific procedures 2 . Male female age ≥18 year 3 . Histological cytological confirmation malignant solid tumour advance metastatic set meet one criterion : Patients resistant refractory standard treatment treatment exist OR Patients suitable effective standard therapy exist OR Patients advance breast cancer anastrozole , letrozole tamoxifen indicate may also enter study ( postmenopausal breast cancer patient eligible cohort ; however , premenopausal breast cancer patient eligible tamoxifen cohort ) . 4 . Patients must normal organ bone marrow function measure within 28 day prior administration study treatment define : Haemoglobin ( Hb ) ≥10.0 g/dL blood transfusion past 28 day Absolute neutrophil count ( ANC ) ≥1.5 x 109/L Platelet count ≥100 x 109/L Total bilirubin ≤1.5 x institutional upper limit normal ( ULN ) ( except case Gilbert 's disease ) Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) ≤2.5 x institutional ULN unless liver metastasis present , case must ≤5x ULN Serum creatinine ≤1.5 x institutional ULN 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 6 . Patients must life expectancy ≥16 week 7 . Evidence nonchildbearing status woman childbearing potential , postmenopausal status : negative urine serum pregnancy test within 28 day study treatment , confirm prior treatment Day 1 Part A. Postmenopausal define : Age ≥ 60 year Age &lt; 60 year amenorrheic 1 year absence chemotherapy and/or hormonal treatment Luteinising hormone ( LH ) , follicle stimulate hormone ( FSH ) plasma oestradiol level postmenopausal range woman 60 year Radiationinduced oophorectomy last menses &gt; 1 year ago Or surgical sterilisation ( bilateral oophorectomy hysterectomy ) 8 . Patients willing able comply protocol duration study include undergoing treatment , schedule visit examination 9 . Patients must stable concomitant medication regimen ( exception electrolyte supplement ) , define change medication dose within 2 week prior start study treatment . 1 . Involvement plan and/or conduct study ( applies AstraZeneca staff , agent , and/or staff study site ) 2 . Previous enrolment present study 3 . Exposure investigational product ( IP ) ( include PARP inhibitor ) within 30 day 5 half life ( whichever longer ) prior enrolment 4 . Prior chemotherapy within 3 week study entry 5 . Prior radiotherapy within 2 week study entry 6 . If prior endocrine treatment give , adequate washout period require : least 2 week anastrozole , least 4 week letrozole least 10 week tamoxifen 7 . Resting ECG QTc &gt; 470 msec detect 2 time point within 24 hour period , family history long QT syndrome . If ECG demonstrate QTc &gt; 470 msec , patient eligible repeat ECG demonstrate QTc &lt; 470 msec . 8 . Patients receive inhibitor inducer CYP3A4 unless wash prior start study treatment . 9 . Persistent toxicity ( Common Toxicity Criteria Adverse Events [ CTCAE ] grade ≥2 ) cause previous cancer therapy , exclude alopecia and/or CTCAE grade 2 peripheral neuropathy 10 . Patients myelodysplastic syndrome/acute myeloid leukaemia 11 . Major surgery within 2 week start study treatment : patient must recover effect major surgery 12 . Patients consider poor medical risk due serious , uncontrolled medical disorder , nonmalignant systemic disease active , uncontrolled seizure active uncontrolled infection . 13 . Patients unable swallow orally administer medication patient gastrointestinal disorder significant gastrointestinal resection likely interfere absorption study medication 14 . Patients gastric , gastrooesophageal , oesophageal cancer 15 . Pregnant breastfeed woman 16 . Patients know active Hepatitis B C , human immunodeficiency virus ( HIV ) . 17 . Patients know hypersensitivity olaparib ( cohort ) , tamoxifen ( Cohort 1 ) anastrozole ( Cohort 2 ) , letrozole ( Cohort 3 ) , excipients product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>oncology , cancer , tumour , neoplasm , anticancer drug , pharmacokinetics , olaparib , anastrozole , tamoxifen , letrozole ,</keyword>
</DOC>